Literature DB >> 33490112

Mechanisms of Podocyte Detachment, Podocyturia, and Risk of Progression of Glomerulopathies.

Hernán Trimarchi1.   

Abstract

BACKGROUND: Glomerulopathies are the main cause of ESRD. Primary or secondary causes of glomerular diseases comprise more than 70% of cases that end up in renal replacement therapies.
SUMMARY: The total glomerular mass that each individual contains is key to maintaining normal kidney function. Diabetes, hypertension, and any primary or secondary glomerulopathy may threaten the normal glomerular function. In fact, any glomerular insult may alter the glomerular filtration barrier, which in turn is composed by the podocyte, the glomerular basement membrane, and the capillary endothelial cell. Deposition of immune complexes, antibodies, or complement components at the subepithelial, intramembranous, or subendothelial space, and mutations in podocyte, slit diaphragm, or glomerular basement membrane proteins or enzymes are the main etiologies of glomerular alterations. Podocytes are glomerular cells that do not divide under normal circumstances. In this respect, maintenance of the absolute podocyte number per glomer-ulus is critical for normal glomerular function. As the insult progresses, podocytes start to detach from the glomerular basement membrane. When the podocyte loss is over 40% in a glomerulus, glomerulosclerosis develops, and obliteration of the glomerulus is the rule. In clinical grounds, this phenomenon is diagnosed mainly by proteinuria and a decline in glomerular filtration rate. KEY MESSAGES: In this review article, the impact of podocyturia in glomerular diseases and the main mechanisms of podocyte detachment are discussed. Finally, potential targets of therapeutic approach are suggested.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Chronic kidney disease; Glomerulopathy; Podocyte; Podocyturia; Proteinuria

Year:  2020        PMID: 33490112      PMCID: PMC7745660          DOI: 10.1159/000507997

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN: 2296-9357


  47 in total

1.  Pathologic classification of focal segmental glomerulosclerosis: a working proposal.

Authors:  Vivette D D'Agati; Agnes B Fogo; Jan A Bruijn; J Charles Jennette
Journal:  Am J Kidney Dis       Date:  2004-02       Impact factor: 8.860

Review 2.  The podocyte's response to stress: the enigma of foot process effacement.

Authors:  Wilhelm Kriz; Isao Shirato; Michio Nagata; Michel LeHir; Kevin V Lemley
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-12

3.  Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases.

Authors:  Larysa Wickman; Farsad Afshinnia; Su Q Wang; Yan Yang; Fei Wang; Mahboob Chowdhury; Delia Graham; Jennifer Hawkins; Ryuzoh Nishizono; Marie Tanzer; Jocelyn Wiggins; Guillermo A Escobar; Bradley Rovin; Peter Song; Debbie Gipson; David Kershaw; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

Review 4.  Podocyte biology for the bedside.

Authors:  J Ashley Jefferson; Charles E Alpers; Stuart J Shankland
Journal:  Am J Kidney Dis       Date:  2011-06-29       Impact factor: 8.860

5.  Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy.

Authors:  Shubha S Bellur; Fanny Lepeytre; Olga Vorobyeva; Stéphan Troyanov; H Terence Cook; Ian S D Roberts
Journal:  Kidney Int       Date:  2016-12-01       Impact factor: 10.612

6.  Interaction of CD80 with Neph1: a potential mechanism of podocyte injury.

Authors:  Bhavya Khullar; Renu Balyan; Neelam Oswal; Nidhi Jain; Amita Sharma; Malik Z Abdin; Arvind Bagga; Shinjini Bhatnagar; Nitya Wadhwa; Uma Chandra Mouli Natchu; Anna George; Satyajit Rath; Vineeta Bal; Shailaja Sopory
Journal:  Clin Exp Nephrol       Date:  2017-10-11       Impact factor: 2.801

7.  Podocyturia as a diagnostic marker for preeclampsia amongst high-risk pregnant patients.

Authors:  Belinda Jim; Pascale Jean-Louis; Andi Qipo; David Garry; Samia Mian; Tulio Matos; Christopher Provenzano; Anjali Acharya
Journal:  J Pregnancy       Date:  2012-02-21

8.  Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.

Authors:  H Trimarchi; M Forrester; F Lombi; V Pomeranz; M S Raña; A Karl; J Andrews
Journal:  Case Rep Nephrol       Date:  2014-05-15

9.  Increased urinary CD80 excretion and podocyturia in Fabry disease.

Authors:  H Trimarchi; R Canzonieri; A Schiel; C Costales-Collaguazo; J Politei; A Stern; M Paulero; T Rengel; J Andrews; M Forrester; M Lombi; V Pomeranz; R Iriarte; A Muryan; E Zotta; M D Sanchez-Niño; A Ortiz
Journal:  J Transl Med       Date:  2016-10-13       Impact factor: 5.531

10.  Quality of Care for Patients With Chronic Kidney Disease in the Primary Care Setting: A Retrospective Cohort Study From Ontario, Canada.

Authors:  Danielle M Nash; Scott Brimble; Maureen Markle-Reid; Eric McArthur; Karen Tu; Gihad E Nesrallah; Allan Grill; Amit X Garg
Journal:  Can J Kidney Health Dis       Date:  2017-05-23
View more
  3 in total

1.  α-Parvin Defines a Specific Integrin Adhesome to Maintain the Glomerular Filtration Barrier.

Authors:  Manuel Rogg; Jasmin I Maier; Clara Van Wymersch; Martin Helmstädter; Alena Sammarco; Maja Lindenmeyer; Paulina Zareba; Eloi Montanez; Gerd Walz; Martin Werner; Nicole Endlich; Thomas Benzing; Tobias B Huber; Christoph Schell
Journal:  J Am Soc Nephrol       Date:  2022-03-08       Impact factor: 14.978

2.  Vitamin D/VDR Protects Against Diabetic Kidney Disease by Restoring Podocytes Autophagy.

Authors:  Zhixia Song; Chao Xiao; Xiaoli Jia; Chunhua Luo; Lang Shi; Rong Xia; Jiefu Zhu; Shizhong Zhang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-16       Impact factor: 3.168

Review 3.  Molecular Mechanisms of Cellular Injury and Role of Toxic Heavy Metals in Chronic Kidney Disease.

Authors:  Manish Mishra; Larry Nichols; Aditi A Dave; Elizabeth H Pittman; John P Cheek; Anasalea J V Caroland; Purva Lotwala; James Drummond; Christy C Bridges
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.